Systematic review: effectiveness and safety of switching between originator infliximab and biosimilar infliximab in patients with inflammatory bowel disease.
Gary R LichtensteinArif SoonasraMark LatymerSheena SinghBrian G Feagan
Published in: Expert opinion on biological therapy (2024)
www.crd.york.ac.uk/prospero identifier is CRD42021289144.